# US 2001/0024653 A1 · Attenuated recombinant mycobacteria useful as immunogens or as vaccine components

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024653 A1
- Document ID: US20010024653A1
- Status: Published application
- Kind: A1
- Application number: 09/851,951
- Filed: 2001-05-09
- Published: 2001-09-27
- Earliest claimed: 1997-06-11
- Assignees: Institut Pasteur
- Inventors: Bridgitte Gicquel; Christophe Guilhot; Mary Jackson
- Web page: https://patentgrep.com/patent/US20010024653A1

## CPC

- C12N 9/1055: {Levansucrase (2.4.1.10)}
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C12N 1/205: Bacterial isolates
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- A61K 2039/522: {avirulent or attenuated}
- C12R 2001/34: Mycobacterium smegmatis
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

This invention provides recombinant mycobacterium strains of pathogenic origin that have been attenuated by the inactivation of a gene coding for a metabolic protein, specifically a gene coding for a protein necessary for the biosynthesis of a purine or a pyrimidine base, and more precisely, the purC gene that codes for an enzyme of the metabolic pathway of purine biosynthesis. The recombinant mycobacterium of this invention have a reduced capacity to propagate in a mammalian host, but remain viable in the host for a period of time sufficient to induce an protective immune response against the natural pathogenic mycobacterium counterpart.

## Claims

### Claim 1

A recombinant mycobacterium strain of pathogenic origin capable of replicating in a macrophage of a host, said strain containing in its chromosome or on a plasmid a counterpart to a gene in the wild type mycobacterium coding for a protein necessary for the biosynthesis of a purine or a pyrimidine base, wherein said counterpart gene in the recombinant mycobacterium has been inactivated by at least one point mutation or by addition, deletion, or substitution of one or more base pairs.

### Claim 2 (depends on 1)

The recombinant mycobacterium strain according to claim 1, wherein said mycobacterium strain belongs to the Mycobacterium tuberculosis complex.

### Claim 3 (depends on 1)

The recombinant mycobacterium strain according to claim 1, wherein said mycobacterium strain belongs to the Mycobacterium avium species.

### Claim 4 (depends on 1)

The recombinant mycobacterium strain according to claim 1, wherein said mycobacterium strain belongs to the Mycobacterium intracellulare species.

### Claim 5 (depends on 1)

The recombinant mycobacterium strain according to claim 1, wherein the gene in the wild type mycobacterium codes for a protein necessary for the biosynthesis of at least one of the following bases chosen among the group consisting of guanine or adenine.

### Claim 6 (depends on 1)

The recombinant mycobacterium strain according to claim 1, wherein the gene in the wild type mycobacterium codes for a protein necessary for the biosynthesis of at least one of the following bases chosen among the group consisting of cytosine, uracil, or thymine.

### Claim 7 (depends on 5)

The recombinant mycobacterium strain according to claim 5, wherein the gene in the wild type mycobacterium is the purC or the purL gene.

### Claim 8

The recombinant mycobacterium strain MYC 1551 (C.N.C.M. No. I-1871).

### Claim 9

The recombinant mycobacterium strain MYC 1552 (C.N.C.M. No. I-1872).

### Claim 10

A recombinant vector containing SacB gene coding for a levane saccharase enzyme and a nucleotide sequence consisting of a gene coding for a protein necessary for the biosynthesis of a purine or a pyrimidine base that has been inactivated by at least one point mutation or by addition, deletion, or substitution of one or more base pairs.

### Claim 11 (depends on 10)

The recombinant vector according to claim 10, wherein said modified gene is a gene coding for a base chosen among the group consisting of guanine or adenine.

### Claim 12 (depends on 10)

The recombinant vector according to claim 10, wherein said modified gene is a gene coding for a base chosen among the group consisting of cytosine, uracil, or thymine.

### Claim 13 (depends on 12)

The recombinant vector according to claim 12, wherein said modified gene is the purC or the purL gene.

### Claim 14 (depends on 10)

The recombinant vector according to claim 10, wherein the gene coding for a protein necessary for the biosynthesis of a purine or a pyrimidine base is interrupted by the insertion of an exogenous polynucleotide.

### Claim 15 (depends on 14)

The recombinant vector according to claim 14, wherein the exogenous polynucleotide is selectable marker gene.

### Claim 16 (depends on 15)

The recombinant vector according to claim 15, wherein the selectable marker gene is a gene coding for resistance to an antibiotic.

### Claim 17 (depends on 16)

The recombinant vector according to claim 16, wherein the antibiotic resistance gene is a gentamycin resistance coding gene or a kanamycin resistance coding gene.

### Claim 18 (depends on 14)

The recombinant vector according to claim 14, wherein the exogenous polynucleotide comprises a gene coding for an antigenic protein heterologous with respect to the mycobacterium strain to be transfected.

### Claim 19 (depends on 13, 15, 16)

The recombinant vector according to any one of claims 13, 15, 16, or 17 which is contained in the recombinant mycobacterium strain MYC 1551 (C.N.C.M. No. I-1871).

### Claim 20 (depends on 13, 15, 16)

The recombinant vector according to any one of claims 13, 15, 16, or 17 which is contained in the recombinant mycobacterium strain MYC 1552 (C.N.C.M. No. I-i 872).

### Claim 21

A purified polynucleotide comprising the SacB gene placed in the neighborhood of a gene coding for a protein necessary for the biosynthesis of a purine or a pyrimidine base that has been inactivated by at least one point mutations or by addition or deletion of one or more base pairs.

### Claim 22 (depends on 1, 10)

A method for producing a recombinant mycobacterium strain according to claim 1 comprising the steps of:
a) providing a vector according to claim 10;
b) transforming the mycobacterium strain with said vector;
c) selecting the clones of the transformed mycobacteria for the replacement of the nucleotide sequence of interest by propagating said transformed clones in a culture medium supplemented with sucrose; and
d) isolating the recombinant strain.

### Claim 23 (depends on 22)

The method according to claim 22 wherein the vector contains a marker gene, and wherein step c) is preceded by a first selection step of transformed clones by propagating said clones in a culture medium supplemented with a selection molecule.

### Claim 24 (depends on 1)

An immunogenic composition comprising a recombinant mycobacterium strain according to claim 1.

### Claim 25 (depends on 1)

A vaccine composition containing a recombinant mycobacterium according to claim 1 in combination with a pharmaceutically compatible excipient.

### Claim 26

A polynucleotide containing all or part of the genome of a mycobacterium strain which is devoid of a wild gene encoding a protein involved in the biosynthesis of a purine or a pyrimidine base.

### Claim 27 (depends on 1)

A recombinant mycobacterium according to claim 1 which has been additionally transformed with a recombinant vector carrying a polynucleotide encoding an antigenic peptide or protein which contains at least one antigenic epitope.

### Claim 28 (depends on 1)

An immunotherapeutic composition comprising a recombinant mycobacterium strain according to claim 1.

### Claim 29 (depends on 28)

The immunotherapeutic composition according to claim 28, wherein the recombinant mycobacterium strain is alive.

### Claim 30 (depends on 28)

The immunotherapeutic composition according to claim 28, wherein the recombinant mycobacterium strain is not alive.

### Claim 31 (depends on 1)

A pharmaceutical composition containing a recombinant mycobacterium strain according to claim 1 together with a pharmaceutically acceptable carrier.

### Claim 32 (depends on 24, 25, 28, 31)

A method of treating or preventing pathogenic mycobacterial infection comprising the step of administering a composition according to any one of claims 24, 25, 28 or 31 to a patient in need thereof.
